Back to today’s briefing

Story perspectives

Dr. Del Conde Champions GLP-1 Drugs for PAD

3/5/2025

39 7

Summary

Story summary

At ISET 2025, Dr. Ian Del Conde captivated the audience with his insights on GLP-1 receptor agonists, such as semaglutide and tirzepatide, in combating peripheral arterial disease (PAD). He passionately advocated for their use in diabetic patients with a BMI over 27, showcasing their remarkable ability to enhance blood flow and significantly lower amputation risks.

1 of 1

Story summary

At ISET 2025, Dr. Ian Del Conde captivated the audience with his insights on GLP-1 receptor agonists, such as semaglutide and tirzepatide, in combating peripheral arterial disease (PAD). He passionately advocated for their use in diabetic patients with a BMI over 27, showcasing their remarkable ability to enhance blood flow and significantly lower amputation risks.